## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- 1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - (a) SEQ ID NO: 214; and
  - (b) the <u>full</u> complement of SEQ ID NO: 214;
  - (c) -- sequences consisting of at least 20 contiguous residues of SEQ ID NO:
- <del>214;</del>
- (d) sequences that hybridize to SEQ ID NO: 214 under highly stringent conditions:
  - (e) -- sequences having at least 75% identity to SEQ ID NO: 214;
  - (f) --- sequences having at least 90% identity to SEQ ID NO: 214 and
  - (g) degenerate variants of SEQ ID NO: 214.
  - 2. (Cancelled).
- 3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
- 4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.
  - 5. (Cancelled).

	6.	(Cancelled).
	7.	(Cancelled).
	8.	(Previously canceled)
	9.	(Cancelled).
	10.	(Cancelled).
selected from	11. m the g	(Previously Presented) A composition comprising a first component roup consisting of physiologically acceptable carriers and immunostimulants, onent selected from the group consisting of the polynucleotides of claim 1.
	12.	(Cancelled).
	13.	(Cancelled).
	14.	(Cancelled).
oligonucleotid	15. de acco	(Currently Amended) A diagnostic kit comprising at least one rding to claim 18.
	16.	(Cancelled).
	17.	(Cancelled).
	18.	(Cancelled).